Journal of Drug Delivery

Novel Oncology Therapeutics: Targeted Drug Delivery for Cancer


Publishing date
25 Jan 2013
Status
Published
Submission deadline
07 Sep 2012

1University of Ioannina, Ioannina, Greece

2Centre for Immunology, Burnet Institute, 85 Commercial Road, Melbourne, VIC 3004, Australia

3Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria

4Human Cancer Biobank Center, University of Ioannina, 45110 Ioannina, Greece; Oncology Section, Medical School, University of Ioannina, 45110 Ioannina, Greece

5Department of Clinical Pharmacy and Diagnostics, University of Vienna, 1090 Vienna, Austria


Novel Oncology Therapeutics: Targeted Drug Delivery for Cancer

Description

Despite the recent progress in the surgery, detection, and prevention of cancer, this disease is projected to become the leading cause of death worldwide. Targeted delivery of cytotoxic agents to special sites or organs is a challenging issue that needs to be addressed in order to surpass systematic toxicity. Due to the complexity of the disease, novel innovations in the early cancer detection and treatment can emerge only upon interscience collaboration.

To this direction, biotechnology and nanotechnology can offer the design and construction of multifunctional nanoparticles that could allow a combinatorial delivery and targeting of therapeutic or diagnostic agents, thus maximizing the efficacy and minimizing the side effects.

This special issue will target to stimulate the scientific community to accumulate the current knowledge on molecularly targeted cancer therapies and innovative methods of drug delivery in cancer. We invite authors to contribute original research articles as well as review articles that will assist to accelerate progress in the early cancer detection and treatment based on innovative tools. Potential topics include, but are not limited to:

  • Drug delivery systems for cancer
  • Metal-based prodrugs as a strategy for drug delivery
  • Tumor-specific drug delivery systems and tumor-targeting chemotherapy
  • Multidrug delivery
  • Nanoformulations containing peptide-drug conjugation agents for tumor targeting
  • Delivery strategies according to cancer type and location
  • Armed monoclonal therapeutics
  • Nanodrug particles based on antisense, RNAi, siRNA, antibodies, and natural products
  • Combined strategies directed against tumoral endothelium
  • Mathematical modeling of drug delivery
  • Therapeutics exploiting cancer-cell transporters
  • Decoy therapeutics that achieve unsuspected cellular entry
  • MRI-guided focused ultrasound as a new method of drug delivery

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jdd/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.